15 results about "Chronic kidney failure" patented technology

The invention discloses a self-supporting membrane type hemodialyzer with a porous structure and a preparation method, the self-supporting membrane type hemodialyzer comprises a polymer solution and a core liquid, the polymer solution comprises the following components by weight: 5-10% of aminated polyether sulfone, 2-6% of a pore-foaming agent, 0.5-3% of a chemical cross-linking agent, and 40-85% of a solvent; the core liquid is prepared from a solvent and a non-solvent, and the concentration ratio of the core liquid is 40%-55%. The fiber is used for kidney replacement treatment of patients with acute and chronic renal failure, the fiber inner diameter is 150-250 microns, the wall thickness is 20-70 microns, the membrane aperture is 1-5 nm, the ultrafiltration coefficient is 15-65 ml / h.mmHg, and the maximum use transmembrane pressure is 500 mmHg. The hemodialysis membrane has good biocompatibility, and for wide patients with different medical requirements, the hemodialysis membrane has high permeability and excellent screening performance on substances such as micromolecular toxins and the like.

Metal-organic framework molecules with pyrene group-containing or biphenyl group-containing linkers for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples from patients suffering from a uremia-related disease, such as chronic kidney failure.

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating chronic renal failure, which is prepared from the following raw material medicines in parts by weight: 6-12 parts of radix bupleuri, 9-18 parts of radix scutellariae, 6-12 parts of ginger processed pinellia, 9-18 parts of radix pseudostellariae, 3-9 parts of honey-fried licorice root, 3-9 parts of leech, 3-9 parts of fructus amomi, 9-18 parts of perilla leaf and 9-18 parts of common fenugreek seed. The traditional Chinese medicine composition aims at symptoms and pathogenesis of the chronic renal failure, adopts treatment principles of tonifying qi, warming yang, dispersing blood stasis and draining turbidity, is cheap in raw materials, simple and convenient to prepare, convenient to use and small in side effect, can be taken for a long time, and has a better curative effect and a good application prospect on the chronic renal failure through observation and analysis.

The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and / or angiotensin AII antagonists and the use thereof for the treatment and / or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and / or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).

The invention discloses a dracocephalum moldavica extract which is prepared by the following steps: by taking a dry overground part or a part which is more than 30cm away from the ground as a medicine part, carrying out reflux extraction by taking 30-50% ethanol as an extraction solvent, filtering an extracting solution, concentrating until no alcohol smell exists, carrying out alcohol precipitation, filtering, re-concentrating filtrate to obtain a concentrated solution, loading the concentrated solution on an HPD600 type macroporous adsorption resin column, and carrying out freeze-drying to obtain the dracocephalum moldavica extract. The preparation method comprises the following steps: firstly eluting with water, then eluting with 20-80% ethanol, collecting 20-80% ethanol eluent, and concentrating to obtain clear paste, or drying the clear paste to obtain dry paste powder. The invention further discloses application of dracocephalum moldavica or the dracocephalum moldavica extract in preparation of drugs for treating and / or preventing chronic kidney diseases.

The present application relates to the field of pharmaceutical chemistry, and particularly relates to application of apigenin and derivatives thereof or pharmaceutically acceptable salts thereof in preparation of drugs for treating or preventing kidney diseases, for example, chronic renal failure diseases. The research results of the present application show that apigenin can obviously improve symptoms of kidney diseases, especially chronic renal failure diseases.

The invention provides a traditional Chinese medicine composition for treating chronic renal failure as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating chronic renal failure is prepared from the following raw materials: rheum officinale, polygonum cuspidatum, leonurus, astragalus membranaceus, dandelion, poria cocos, plantain herb, herba lycopi, white mulberry root-bark, radix paeoniae alba and eclipta. The traditional Chinese medicine composition adjusts traditional Chinese medicine components, follows the compatibility principle of monarch, minister, assistant and guide and the structure theory, reasonably organizes medicines, enhances the curative effect, reduces toxic and side effects, comprehensively takes care of the illness state, improves the treatment effect of the traditional Chinese medicine composition on chronic renal failure, adjusts the abnormal levels of serum urea nitrogen and serum creatinine, and improves calcium and phosphorus metabolism disorder.

1. The name of this design product: hemodialysis filter. 2. Purpose of the product of this design: Used for hemodialysis, hemofiltration, and hemodiafiltration treatment for patients with acute or chronic renal failure. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The present invention relates to a new process for the preparation of heterocyclic derivative compounds of Formula I; to new intermediate compounds used in said process for the preparation; to compositions for the treatment or prevention of hyperuricemia, gout disease, nephritis, chronic renal failure, kidney stones, uremia, urinary stones or uric acid-related diseases, said compositions comprising a compound of Formula I at a dosage of administration of more than 2 mg to 10 mg below, administered orally once a day; and to new hydrochloride 1.5 hydrate salts of compounds of Formula I.

To provide an ATP production promoter useful for preventing or treating diseases associated with decreased ATP production, particularly renal impairment. [Solution] The present invention comprises an ATP production promoter containing a component having URAT1 inhibitory activity. Preferably, the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad. The present invention is expected to be useful as a preventive and therapeutic agent for diseases of decreased ATP production, and is particularly useful as a therapeutic and / or preventive agent for nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia nephropathy, autosomal dominant tubulointerstitial kidney disease, nephronoplasia, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.

The present invention relates to the field of hemodialysis technology, and more specifically, to a glacial acetic acid dialysis concentrate and a preparation method thereof. The present invention provides an anti-coagulation factor VIII antibody, and applies the antibody to the preparation of a glacial acetic acid dialysis concentrate. Analysis of the results shows that the introduction of the anti-coagulation factor VIII antibody significantly improves the blood coagulation phenomenon of the glacial acetic acid dialysis concentrate, and reduces the risk of increased coagulation and thrombosis in commercial glacial acetic acid dialysis fluid. At the same time, the stability of the dialysis fluid can be effectively improved, and the dialysis fluid can be suitable for long-term storage without deterioration. The application prospects of glacial acetic acid dialysis fluid are significantly improved, especially for hemodialysis of patients with acute and chronic renal failure and patients with drug poisoning, which will bring many advantages.

The invention discloses an antibody for detecting p-cresol sulfate and related products and application thereof, the antibody can specifically bind to p-cresol sulfate and has high binding activity, the antibody can rapidly and accurately quantify the content of p-cresol sulfate in a sample to be detected through convenient methods such as ELISA and immunochromatography, and the antibody can be applied to the detection of p-cresol sulfate. The clinical early screening requirement on the chronic renal failure patient can be met, the change of the metabolite level in the treatment process can be dynamically tracked, an objective basis is provided for illness state evaluation and treatment scheme adjustment, and the application prospect is wide.

The invention relates to the technical field of medicine analysis, in particular to a method for researching the pharmacodynamic material basis and action mechanism of renal failure recovery granules. The method comprises the following steps: S1, detecting blood entering components of the renal failure recovery granules; s2, screening intersection targets of the blood entering components of the renal failure complex granules and the renal failure; s3, constructing a protein interaction network, and screening core targets of the renal failure complex granules for treating chronic renal failure; s4, carrying out GO and KEGG enrichment analysis on the core target spot; and S5, carrying out molecular docking by taking the blood entering component of the renal failure complex granules as a ligand and taking the core target as a receptor. According to the method, the blood entering components of the renal failure complex granules are detected, then the material basis and the action mechanism of the renal failure complex granules for treating the CRF are clarified through network pharmacology and molecular docking technologies, and a basis is provided for further research and clinical application of the renal failure complex granules for treating the CRF.

This invention discloses a traditional Chinese medicine composition for treating chronic renal failure and its application. The composition is made from Astragalus membranaceus, Epimedium, Salvia miltiorrhiza, Rheum palmatum, Orthosiphon aristatus, Uncaria rhynchophylla, Centella asiatica, Pyrola rotundifolia, Smilax glabra, Euonymus alatus, and Sargassum fusiforme in specific weights. The composition significantly reduces serum creatinine, blood urea nitrogen, and 24-hour urinary protein levels in rats with a chronic renal failure model, effectively improving renal pathological damage. Its mechanism of action may be related to multi-target effects such as regulating local renal inflammatory factors. Through rational formulation, this composition fully utilizes the synergistic effects of its components, exhibiting advantages such as definite efficacy and minimal side effects.

The invention discloses lactobacillus crispatus capable of improving chronic renal failure and a metagen thereof, and belongs to the technical field of microbial application, lactobacillus crispatus WZA-LC10 is separated from human excrement, and the biological preservation number of the lactobacillus crispatus WZA-LC10 is CCTCC (China Center for Type Culture Collection) NO: M 20241764. According to the invention, a strain of lactobacillus crispatus WZA-LC10 is screened out and is combined with a medicinal and edible extract, and the lactobacillus crispatus and the metaplasts thereof can effectively promote the recovery of kidney functions and delay the progress of a disease course by improving intestinal health, enhancing immunity and regulating in-vivo metabolism; by adopting the design of replacing viable bacteria with the postbiotics, the problem of flora imbalance or infection possibly caused by the viable bacteria is avoided, the stability of the product is improved, meanwhile, the postbiotics provide various metabolites, have the effects of oxidation resistance, inflammation resistance, immunoregulation and the like, ensure the safety of long-term use, and are suitable for daily health maintenance and prevention of chronic renal failure.